{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T16:15:17Z","timestamp":1726071317569},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s69211","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T01:42:55Z","timestamp":1428370975000},"page":"549","source":"Crossref","is-referenced-by-count":2,"title":["Profile of pomalidomide and its potential in the treatment of myelofibrosis"],"prefix":"10.2147","author":[{"given":"Ruben","family":"Mesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisstina","family":"Gowin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,4]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=24449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:30:27Z","timestamp":1477866627000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/profile-of-pomalidomide-and-its-potential-in-the-treatment-of-myelofib-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s69211","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}